| Hospitals’ use of electronic health records data, 2015–2017 S Parasrampuria, J Henry ONC Data Brief 46 (1), 13, 2019 | 49 | 2019 |
| Market exclusivity for drugs with multiple orphan approvals (1983–2017) and associated budget impact in the US WV Padula, S Parasrampuria, MP Socal, RM Conti, GF Anderson PharmacoEconomics 38, 1115-1121, 2020 | 18 | 2020 |
| Trends in prescription drug spending, 2016-2021 S Parasrampuria, S Murphy Washington, DC: office of the assistant secretary for planning and evaluation, 2022 | 11 | 2022 |
| Interoperability among office-based physicians in 2015 and 2017 V Patel, Y Pylypchuk, S Parasrampuria, L Kachay ONC Data Brief 47, 1-12, 2019 | 11 | 2019 |
| Impact of electronic prescribing of controlled substances on opioid prescribing: evidence from I-STOP program in New York Y Pylypchuk, S Parasrampuria, C Smiley, T Searcy Medical Care Research and Review 79 (1), 114-124, 2022 | 8 | 2022 |
| Comparison of out-of-pocket spending on ultra-expensive drugs in medicare part D vs commercial insurance MJ DiStefano, SY Kang, S Parasrampuria, GF Anderson JAMA Health Forum 4 (5), e231090-e231090, 2023 | 7 | 2023 |
| Comparing patient OOP spending for specialty drugs in Medicare Part D and employer-sponsored insurance S Parasrampuria The American Journal of Managed Care 26 (9), 2020 | 7 | 2020 |
| Value and performance of accountable care organizations: a cost-minimization analysis S Parasrampuria, AH Oakes, SS Wu, MA Parikh, WV Padula International Journal of Technology Assessment in Health Care 34 (4), 388-392, 2018 | 7 | 2018 |
| Modifying the criteria for granting orphan drug market exclusivity MP Socal, S Parasrampuria, GF Anderson Value in Health 23 (11), 1470-1476, 2020 | 6 | 2020 |
| Is the Orphan Drug Act Being used as a Loophole to Extend Periods of Drug Exclusivity? WV Padula, S Parasrampuria, M Socal, G Anderson Value in Health 21, S89, 2018 | 3 | 2018 |
| Disaggregating the dementia monolith: An analysis of variation in Medicare costs and use by dementia subtype S Parasrampuria, E Bijelic, DM Bott, J Driessen, MJ Lipp, SM Ling Alzheimer's & Dementia 19 (8), 3295-3305, 2023 | 2 | 2023 |
| Catastrophic Coverage in the Medicare Part D Drug Benefit: Which Beneficiaries Need It and How Much Are They Spending? AP Sen, S Parasrampuria, KE Anderson, G Anderson Commonwealth Fund. https://www. commonwealthfund. org/publications/issue …, 2020 | 2 | 2020 |
| FDA User Fees: Examining Changes in Medical Product Development and Economic Benefits S Parasrampuria, T Beleche Office of the Assistant Secretary for Planning and Evaluation (ASPE), 2023 | 1 | 2023 |
| Effects of an out-of-pocket maximum in Medicare Part D. S Parasrampuria, GF Anderson American Journal of Managed Care 28 (2), 2022 | 1 | 2022 |
| COST OF GENERIC DRUG DEVELOPMENT AND APPROVAL FINAL S PARASRAMPURIA, A SERTKAYA, A LORD, C BERGER | 1 | 2021 |
| The Potential Role of The Nonprofit Pharmaceutical Industry in Addressing Shortages and Increasing Access to Essential Medicines and Low-Cost Medicines O Adetunji, JF Oliver, S Parasrampuria, G Singson, T Beleche | | 2024 |
| Hospice Coding and Data Conventions Contribute to Oversimplify the Presence of Dementia in Hospice J Driessen, S Parasrampuria, E Bijelic, DM Bott, SM Ling Journal of the American Medical Directors Association, 105070, 2024 | | 2024 |
| EE42 Value of Being the First Biosimilar Entrant JD McGeeney, A Sertkaya, S Parasrampuria, M Lanthier, T Beleche, ... Value in Health 27 (6), S64, 2024 | | 2024 |
| Premarket Notifications and Patents for Breast Pumps Before and After the ACA O Adetunji, P Pemmireddy, T Beleche, S Parasrampuria JAMA, 2024 | | 2024 |
| ASPE Report: Competition in Prescription Drug Markets, 2017-2022 S Parasrampuria, S Murphy Office of the Assistant Secretary for Planning and Evaluation (ASPE), 2023 | | 2023 |
